Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.50 EUR
Change Today +0.01 / 0.40%
Volume 684.9K
SRN On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 11:30 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

sorin spa (SRN) Snapshot

Open
€2.50
Previous Close
€2.49
Day High
€2.52
Day Low
€2.48
52 Week High
03/6/15 - €3.07
52 Week Low
10/15/14 - €1.63
Market Cap
1.2B
Average Volume 10 Days
811.0K
EPS TTM
€0.11
Shares Outstanding
478.7M
EX-Date
--
P/E TM
22.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for SORIN SPA (SRN)

Related News

No related news articles were found.

sorin spa (SRN) Related Businessweek News

No Related Businessweek News Found

sorin spa (SRN) Details

Sorin S.p.A., together with its subsidiaries, researches, develops, and delivers various therapeutic solutions to treat cardiovascular pathologies. It operates through Cardiac Surgery and Cardiac Rhythm Management (CRM) business units. The company provides disposable biomedical devices and systems, including heart-lung machines, oxygenators, autotransfusion systems and devices, mechanical heart valves, tissue heart valves, structureless valves, and annuloplasty rings for extracorporeal circulation during surgery. It also provides defibrillators and pacemakers, and systems for cardiac resynchronisation treatment, patient management, and cardiac arrhythmia assessment. In addition, the company offers single-use systems for urology, urodynamics, cardiac surgery, and haemodialysis. It serves hospitals, healthcare institutions, distributors, organised purchase groups, and government and private entities in Italy, rest of Europe, North America, and internationally. The company was incorporated in 2004 and is headquartered in Milan, Italy.

3,911 Employees
Last Reported Date: 04/2/15
Founded in 2004

sorin spa (SRN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €713.0K
Chairman, President and Chairman of Executive...
Total Annual Compensation: €629.0K
Compensation as of Fiscal Year 2014.

sorin spa (SRN) Key Developments

Sorin Group Announces Positive One-Year Safety and Efficacy Data from North American Prospective Trial of Freedom Solo Stentless Pericardial Aortic Valve

Sorin Group announced positive one-year safety and efficacy data from a North American prospective trial of Freedom Solo Stentless Pericardial Aortic Valve. The trial results, which are available online at the European Journal of Cardio-Thoracic Surgerywebsite, were used to obtain FDA approval of Solo Smart in June 2014. In clinical use since 2004, Freedom Solo is a stentless biological prosthesis that provides optimum blood flow and can be implanted faster than other available stentless valves due to a single suture line technique. Solo Smart is based on the same technology platform, but includes a removable stent for straightforward implantation and optimal positioning. 251 patients with aortic valve disease from 15 centers across North America were included in the trial. The mean age was 74.7 ± 7.5 years and concomitant procedures, primarily coronary artery bypass grafting (CABG), were performed in 61.9% of patients at time of implantation. Preoperatively, 54% of patients had NYHA functional class III or IV symptoms. The study demonstrated excellent hemodynamics in terms of Mean Pressure Gradients and Effective Orifice Area at implantation that remained stable up to 1 year. One-year mean gradients for valve sizes 19, 21, 23, 25 and 27 mm were 11.7, 7.8, 6.3, 4.6 and 5.0 mmHg, respectively. At one-year follow-up, 96% of patients (181/189) were in NYHA class I or II functional status, and freedom from structural valve deterioration was 99.5%.

Sorin SpA Presents at Medical Device Conference 2015, Jun-26-2015 10:50 AM

Sorin SpA Presents at Medical Device Conference 2015, Jun-26-2015 10:50 AM. Venue: Palace Hotel, 2 New Montgomery Street, San Francisco, California, United States. Speakers: Edward S. Andrle, Vice President of Strategy & Business Development.

Sorin Group Announces the Launch of KORA 250

Sorin Group announced the launch of KORA 250, its new generation of full body MRI (Magnetic Resonance Imaging) conditional pacemakers. KORA 250 SR and DR pacemakers, when implanted with the Sorin BEFLEX pacing lead, allow implanted patients to undergo MRI scans on any region of the body. Pacemaker patients are prone to develop medical conditions such as arthritis, cancer or stroke, and may therefore require MRI examinations for optimal disease diagnosis and management. The unique Automatic MRI Mode makes MRI scans safe and efficient for pacemaker patients, automatically detecting the MRI scanner’s magnetic field and ensuring appropriate pacemaker operation during the scan. After the scan, the device automatically returns to normal configuration. As a result, unlike other pacing systems, KORA 250 minimizes the amount of time that patients experience MRI mode. Designed to proactively manage comorbidities, KORA 250 is equipped with advanced therapeutic and diagnostic features, including: SafeR, a unique pacing mode that intelligently manages all types of AV block. SafeR is the only algorithm proven to dramatically reduce right ventricular pacing for patients with AV block as well as patients with sinus node disease. SafeR has also been shown to reduce the risk of heart failure and cardiac hospitalization by 51%; and Sleep Apnea Monitoring (SAM), a clinically validated tool to efficiently screen and monitor patients for severe sleep apnea. Recent studies have highlighted the risks of sleep apnea, a significant comorbidity associated with atrial fibrillation and heart failure.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRN:IM €2.50 EUR +0.01

SRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $172.63 USD +1.27
Edwards Lifesciences Corp $147.48 USD +2.36
Smith & Nephew PLC 1,068 GBp -14.00
Stentys €5.21 EUR +0.04
Zimmer Biomet Holdings Inc $109.77 USD +0.98
View Industry Companies
 

Industry Analysis

SRN

Industry Average

Valuation SRN Industry Range
Price/Earnings 30.4x
Price/Sales 1.5x
Price/Book 1.9x
Price/Cash Flow 13.8x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORIN SPA, please visit www.sorin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.